DFX Intelligence
Agios Pharmaceuticals
Venture-backed company · Stage unknownagios.com
As of · the latest observation of this company; each round carries its own date
Public company. Publicly listed (AGIO); its private filings are not venture rounds.
As of · the latest observation of this company; each round carries its own date
What matters now
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
Drawing the relationship network…
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- unknown
- Rounds on record
- 2
- Disclosed raised
- unknownsum of rounds with a disclosed amount only
- Named investors
- 1
Financing history
2 rounds
- Nov 16, 2011Form D equity offering · $78.0M (form d sold)Arch Venture Partners via Robert Taylor NelsenFact Form D · “Agios Pharmaceuticals Inc Form D, first filed 2011-11-22”
- Apr 14, 2010Form D equity offering · $8.8M (form d sold)Arch Venture Partners via Robert Taylor NelsenFact Form D · “Agios Pharmaceuticals Inc Form D, first filed 2010-04-26”
Who would invest
How comparable investors are foundComparable investors backed two or more of the companies this company’s own investors also back. Broader fit co-invested two or more times with them and dated a new company in the last 12 months. Each reason is a fact on record: a shared company, a co-investment count, a dated deal, a stage or round size it has joined. A shared sector alone never puts a firm here. Nothing is a prediction that a firm will invest.1 investor on record, then the firms most like them
Already invested
1 investor on record- Arch Venture Partners portfolio listing Fact archventure.com
- Arch Venture Partners form d related, Robert Taylor Nelsen (strongly supported) Inference sec.gov
- Arch Venture Partners form d related, Robert Taylor Nelsen (strongly supported) Inference sec.gov
Strong comparable investors
16 firmsFirms that backed two or more of the companies this company's own investors also back.
- Foresite Capital
- Backed 5 companies this company's investors also back
- Co-invested 5 times with 1 of this company's investors
- Has joined rounds of $50M to $150M (2 on record)
- 1 new company dated in the last 12 months, latest Mar 26, 2026
- Followed on in 33% of its companies
- Omega Fund Management, LLC
- Backed 5 companies this company's investors also back
- Co-invested 5 times with 1 of this company's investors
- Has joined rounds of $50M to $150M (1 on record)
- 1 new company dated in the last 12 months, latest Dec 19, 2025
- 1 fund raising or deploying (newest vintage 2023)
- Decheng Capital LLC
- Backed 3 companies this company's investors also back
- Co-invested 6 times with 1 of this company's investors
- Has joined rounds of $50M to $150M (4 on record)
- 3 new companies dated in the last 12 months, latest Aug 14, 2026
- Followed on in 22% of its companies
+13 more comparable investors
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Broader fit
0 firmsFirms that co-invest repeatedly with this company's investors and dated a new company in the last 12 months.
No other firm co-invests repeatedly with this company's investors on record.
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.none on record
Outcome stated by investors
Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.
Evidence: 1 listingeach firm's own card, as read
- Status not stated on Arch Venture Partners · the firm's card prints no outcome · read Sep 30, 2026 archventure.com“Agios Pharmaceuticals”
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.none on record
No lender position matched to this company.
People
0 officers, 0 directors
No officer or director on record.
Timeline
0 events
No dated event on record.
Evidence
3 observations
Every observation on this company
- Listed on portfolio page: Sep 30, 2026 Fact
- Listed on portfolio page: Sep 16, 2026 Fact
- Listed on portfolio page: Sep 14, 2026 Fact